276 related articles for article (PubMed ID: 33980820)
21. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
Xiong Y; Zhang M; Li Y
Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
[TBL] [Abstract][Full Text] [Related]
22. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
23. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
[TBL] [Abstract][Full Text] [Related]
24. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
25. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
[TBL] [Abstract][Full Text] [Related]
26. Role of plant CBP/p300-like genes in the regulation of flowering time.
Han SK; Song JD; Noh YS; Noh B
Plant J; 2007 Jan; 49(1):103-14. PubMed ID: 17144897
[TBL] [Abstract][Full Text] [Related]
27. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
Gou P; Zhang W
Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of CBP/p300 HAT by A-485 results in suppression of lipogenesis and hepatic gluconeogenesis.
Zhou F; Liu Q; Zhang L; Zhu Q; Wang S; Zhu K; Deng R; Liu Y; Yuan G; Wang X; Zhou L
Cell Death Dis; 2020 Sep; 11(9):745. PubMed ID: 32917859
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
30. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.
Aikawa Y; Nguyen LA; Isono K; Takakura N; Tagata Y; Schmitz ML; Koseki H; Kitabayashi I
EMBO J; 2006 Sep; 25(17):3955-65. PubMed ID: 16917507
[TBL] [Abstract][Full Text] [Related]
31. Polycomb inhibits histone acetylation by CBP by binding directly to its catalytic domain.
Tie F; Banerjee R; Fu C; Stratton CA; Fang M; Harte PJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):E744-53. PubMed ID: 26802126
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity.
Inagaki Y; Shiraki K; Sugimoto K; Yada T; Tameda M; Ogura S; Yamamoto N; Takei Y; Ito M
Int J Oncol; 2016 Feb; 48(2):533-40. PubMed ID: 26676548
[TBL] [Abstract][Full Text] [Related]
34. Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts.
Krošel M; Gabathuler M; Maciukiewicz M; Moser L; Lee GI; Marks M; Tomšič M; Distler O; Ospelt C; Klein K
J Autoimmun; 2021 Sep; 123():102709. PubMed ID: 34304080
[TBL] [Abstract][Full Text] [Related]
35. p300/CBP acetyl transferases interact with and acetylate the nucleotide excision repair factor XPG.
Tillhon M; Cazzalini O; Nardo T; Necchi D; Sommatis S; Stivala LA; Scovassi AI; Prosperi E
DNA Repair (Amst); 2012 Oct; 11(10):844-52. PubMed ID: 22954786
[TBL] [Abstract][Full Text] [Related]
36. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
Chakraborty S; Senyuk V; Sitailo S; Chi Y; Nucifora G
J Biol Chem; 2001 Nov; 276(48):44936-43. PubMed ID: 11568182
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA.
Deng L; Wang D; de la Fuente C; Wang L; Li H; Lee CG; Donnelly R; Wade JD; Lambert P; Kashanchi F
Virology; 2001 Oct; 289(2):312-26. PubMed ID: 11689053
[TBL] [Abstract][Full Text] [Related]
39. P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain.
Iioka T; Furukawa K; Yamaguchi A; Shindo H; Yamashita S; Tsukazaki T
J Bone Miner Res; 2003 Aug; 18(8):1419-29. PubMed ID: 12929931
[TBL] [Abstract][Full Text] [Related]
40. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
